OSAKA, Japan, Oct. 30, 2025 /PRNewswire/ -- On the evening of October 12, 2025, the Osaka Expo 2025 witnessed a highlight moment before its closing—the China Pavilion stood out among 25 large self-built pavilions worldwide and won the Gold Medal in the Large Self-built Pavilion Exhibition Category awarded by the Burea...
OSAKA, Japan, Oct. 30, 2025 /PRNewswire/ -- On the evening of October 12, 2025, the Osaka Expo 2025 witnessed a highlight moment before its closing—the China Pavilion stood out among 25 large self-built pavilions worldwide and won the Gold Medal in the Large Self-built Pavilion Exhibition Category awarded by the Burea...
YANTAI, China, Oct. 30, 2025 /PRNewswire/ -- The 20th China Public Security Expo (CPSE), recognised as the world's premier security exhibition, commenced in Shenzhen on October 28, drawing over 1,000 exhibitors. Raythink Technology Co., Ltd. ("Raythink"), a pioneer in thermal imaging, drew significant attenti...
YANTAI, China, Oct. 30, 2025 /PRNewswire/ -- The 20th China Public Security Expo (CPSE), recognised as the world's premier security exhibition, commenced in Shenzhen on October 28, drawing over 1,000 exhibitors. Raythink Technology Co., Ltd. ("Raythink"), a pioneer in thermal imaging, drew significant attenti...
Collaboration sets a new benchmark for digital transformation in China's freight industry. HONG KONG, Oct. 30, 2025 /PRNewswire/ -- IQAX, a global leader in digital trade intelligence technology, has entered a strategic partnership with CargoNPay, a premier logistics technology platform based in China. This collabora...
Collaboration sets a new benchmark for digital transformation in China's freight industry. HONG KONG, Oct. 30, 2025 /PRNewswire/ -- IQAX, a global leader in digital trade intelligence technology, has entered a strategic partnership with CargoNPay, a premier logistics technology platform based in China. This collabora...
SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. Building on ArkBio's prev...
SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. Building on ArkBio's prev...